GILGAMESH PHARMA INC.

Profile

Company Names

GILGAMESH PHARMA INC.

Addresses

113 UNIVERSITY PLACE, SUITE 1019, NEW YORK, NY 10003

Phone Numbers

929-723-4861

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

2025

State Incorporated:

DELAWARE

Total Amount Raised:

$68,340,946.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2026-03-27 
$2,250,000.00 
$15,000,000.00 
$12,750,000.00 
 
2
2026-03-09 
$60,000,000.00 
$60,000,000.00 
$0.00 
Equity 
1
2026-01-02 
$6,090,946.00 
$6,090,946.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ROBERT 
 
BERMAN 
DIRECTOR
DEAL AM, LLC   |  COPYTELE INC   |  GILGAMESH PHARMACEUTICALS, INC.   |  OSMOL THERAPEUTICS, INC.   |  GILGAMESH PHARMA INC.
ZIA 
 
HUQUE 
DIRECTOR
PRIME MOVERS LAB FUND III-A LP   |  PARADROMICS, INC.   |  HALO INDUSTRIES, INC.   |  GILGAMESH PHARMA INC.
ANDREW 
 
KRUEGEL 
EXECUTIVE OFFICER, DIRECTOR
GILGAMESH PHARMACEUTICALS, INC.   |  GILGAMESH PHARMA INC.
AMY 
 
KRUSE 
DIRECTOR
GILGAMESH PHARMACEUTICALS, INC.   |  PARADROMICS, INC.   |  IRIDIA, INC.   |  COGNIXION CORP   |  MORPHOCEUTICALS, INC.   |  SATORI NEURO PARTNERS LP   |  MOTIF NEUROTECH, INC.   |  SATORI NEURO CO-INVEST LP   |  GILGAMESH PHARMA INC.
PHIL 
 
SKOLNICK 
DIRECTOR
GILGAMESH PHARMACEUTICALS, INC.   |  GILGAMESH PHARMA INC.
JONATHAN 
 
SPORN 
EXECUTIVE OFFICER, DIRECTOR
GILGAMESH PHARMACEUTICALS, INC.   |  GILGAMESH PHARMA INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2026-03-31
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2026-03-27 
2026-03-24
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2026-03-09 
2026-02-04
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2026-01-02 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#